Vertex Pharmaceuticals Incorporated (VRTX) Earnings History
Annual and quarterly earnings data from 1991 to 2025
Loading earnings history...
VRTX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
VRTX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 85.0% | 39.4% | 32.7% |
| 2024 | 86.1% | -2.1% | -4.9% |
| 2023 | 87.2% | 38.8% | 36.7% |
| 2022 | 87.9% | 48.2% | 37.2% |
| 2021 | 88.1% | 36.7% | 30.9% |
Download Data
Export VRTX earnings history in CSV or JSON format
Free sign-in required to download data
Vertex Pharmaceuticals Incorporated (VRTX) Earnings Overview
As of May 6, 2026, Vertex Pharmaceuticals Incorporated (VRTX) reported trailing twelve-month net income of $4.34B, reflecting +836.5% year-over-year growth. The company earned $16.93 per diluted share over the past four quarters, with a net profit margin of 32.7%.
Looking at the long-term picture, VRTX's 5-year EPS compound annual growth rate (CAGR) stands at +8.3%, showing solid earnings momentum. The company achieved its highest annual net income of $3.95B in fiscal 2025, representing a new all-time high.
Vertex Pharmaceuticals Incorporated maintains industry-leading profitability with a gross margin of 85.0%, operating margin of 39.4%, and net margin of 32.7%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including REGN ($4.42B net income, 31.4% margin), ALNY ($577M net income, 8.4% margin), BMRN ($269M net income, 10.8% margin), VRTX has outperformed on profitability metrics. Compare VRTX vs REGN →
VRTX Earnings vs Peers
Earnings metrics vs comparable public companies
VRTX Historical Earnings Data (1991–2025)
35 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $3.95B | +838.1% | $4.76B | $15.32 | 32.7% | 39.4% |
| 2024 | -$536M | -114.8% | -$233M | $-2.08 | -4.9% | -2.1% |
| 2023 | $3.62B | +9.0% | $3.83B | $13.89 | 36.7% | 38.8% |
| 2022 | $3.32B | +41.8% | $4.31B | $12.82 | 37.2% | 48.2% |
| 2021 | $2.34B | -13.6% | $2.78B | $9.01 | 30.9% | 36.7% |
| 2020 | $2.71B | +130.4% | $2.86B | $10.29 | 43.7% | 46.0% |
| 2019 | $1.18B | -43.9% | $1.20B | $4.51 | 28.3% | 28.8% |
| 2018 | $2.10B | +695.8% | $635M | $8.09 | 68.8% | 20.8% |
| 2017 | $263M | +335.1% | $123M | $1.04 | 10.6% | 5.0% |
| 2016 | -$112M | +79.9% | $10M | $-0.46 | -6.6% | 0.6% |
Full VRTX Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See VRTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VRTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VRTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonVRTX — Frequently Asked Questions
Quick answers to the most common questions about buying VRTX stock.
Is VRTX growing earnings?
VRTX EPS is $16.93, with earnings growth accelerating to +836.5%. This exceeds the 5-year CAGR of +8.3%. TTM net income reached $4.3B.
What are VRTX's profit margins?
Vertex Pharmaceuticals Incorporated net margin is +32.7%, with operating margin at +39.4%. Above-average margins indicate pricing power.
How consistent are VRTX's earnings?
VRTX earnings data spans 1991-2025. The accelerating earnings trend is +836.5% YoY. Historical data enables comparison across business cycles.